Postpartum Low Libido and Clinical Trials: How to Find the Right Study for You

What Is Postpartum Low Libido and Why Is It So Common?

Low libido after giving birth is one of the most common and least discussed changes new mothers experience. Studies report that between 68% and 83% of women describe reduced sexual interest in the first three months postpartum, making it far more common than postpartum depression, which affects roughly 10-15% of mothers. Yet it rarely gets the same clinical attention.

The medical term for persistent, distressing low desire is Hypoactive Sexual Desire Disorder (HSDD). HSDD is defined as recurrent deficiency of sexual fantasies and desire for sexual activity that causes personal distress, and it applies specifically when the loss bothers you, not just when a partner notices. The postpartum period creates a near-perfect biological setup for this condition.

The Hormonal Crash That Starts at Delivery

Within 24 hours of delivering the placenta, progesterone and estradiol fall by more than 90%. Estradiol, which averaged 15,000-25,000 pg/mL at term, plummets to levels that overlap with surgical menopause. This is not a gradual transition. It is one of the fastest hormone shifts the human body experiences.

At the same time, prolactin, the hormone that drives milk production, rises sharply. Prolactin suppresses gonadotropin-releasing hormone (GnRH), which means the pituitary produces less LH and FSH, and the ovaries produce less estrogen and testosterone. If you are breastfeeding, this suppression continues for as long as you nurse frequently, sometimes for 12-18 months or longer.

Fatigue, Pain, and the Non-Hormonal Factors

Hormones explain a lot, but not everything. Perineal trauma, cesarean recovery, and dyspareunia affect a substantial proportion of new mothers and independently reduce desire. Sleep deprivation alters cortisol rhythms and suppresses dopamine signaling, both of which are relevant to arousal. Relationship stress, identity shift, and body-image changes also contribute. Any honest clinical framework has to account for all of these layers, not just the endocrine picture.

How Breastfeeding Specifically Changes Your Sexual Physiology

If you are breastfeeding, your hormonal environment is meaningfully different from a non-nursing postpartum woman, and this matters for both treatment decisions and clinical trial eligibility.

Prolactin, Estrogen, and the Vaginal Effects

Sustained high prolactin keeps estrogen low. Low estrogen causes vaginal dryness, reduced lubrication, and thinning of vaginal epithelium, a cluster of changes that mirrors Genitourinary Syndrome of Menopause (GSM) but is more accurately called lactational atrophy. Studies using vaginal pH measurement show that lactating women have vaginal pH values above 5.0, comparable to postmenopausal women, contributing to both discomfort during sex and susceptibility to infections.

This matters clinically because dyspareunia (painful intercourse) and low desire are distinct but interacting problems. Treating only desire without addressing vaginal atrophy often produces partial results. Low-dose vaginal estrogen (estradiol cream 0.01%, vaginal estradiol tablet, or the estradiol vaginal ring) is considered compatible with breastfeeding by the American College of Obstetricians and Gynecologists because systemic absorption is minimal at low doses, though a frank conversation with your provider is warranted before starting.

Testosterone in the Postpartum Period

Testosterone, which contributes to libido in women, is also suppressed during lactation. Free testosterone levels in lactating women are measurably lower than in non-lactating postpartum women or cycling women. No testosterone product is currently FDA-approved for women in the United States, and none has been formally studied in lactating populations. This is a significant evidence gap, and any extrapolation from non-postpartum female testosterone data should be labeled as such.

The Evidence Gap: What We Know and What We Are Still Missing

Women have been systematically underrepresented in sexual medicine trials. Of the two FDA-approved medications for HSDD in premenopausal women (flibanserin and bremelanotide), neither was studied in a postpartum or lactating cohort. This means every clinical recommendation for breastfeeding women with HSDD is extrapolated from data in cycling, non-pregnant women, combined with lactation pharmacokinetic modeling where it exists.

The ACOG Committee Opinion on Female Sexual Dysfunction acknowledges this gap explicitly, stating that evidence-based treatments for postpartum sexual dysfunction remain "limited" and that clinicians should individualize management based on symptom profile and lactation status.

Three specific knowledge gaps affect postpartum women right now:

1. No large randomized controlled trial has compared any pharmacological intervention specifically in postpartum women with HSDD as the primary endpoint.
2. Lactation safety data for flibanserin and bremelanotide consists of animal studies and theoretical pharmacokinetic modeling, not human milk studies.
3. Testosterone therapy for women postpartum has no published RCT data, despite being used off-label by some practitioners.

This is precisely why clinical trial participation matters. The research that will one day answer these questions depends on postpartum women volunteering for studies.

Existing Treatment Options and What the Evidence Says

Even without postpartum-specific trials, there are evidence-based and evidence-informed approaches. Understanding what is available helps you assess whether a clinical trial is studying something new and worthwhile.

Non-Pharmacological Approaches

Mindfulness-based cognitive therapy for sexual dysfunction, studied by Lori Brotto and colleagues at UBC, produced significant improvements in desire and arousal in premenopausal women with HSDD in randomized trials. Couples therapy and sex therapy have supporting evidence in mixed populations. These approaches carry no lactation risk and are a reasonable first step.

Pelvic floor physical therapy, while primarily targeting pain rather than desire, removes a barrier to sex that indirectly depresses libido. ACOG Practice Bulletin No. 198 supports referral to pelvic floor PT for postpartum urinary and pelvic dysfunction.

Flibanserin (Addyi)

Flibanserin is a serotonin 1A agonist and serotonin 2A antagonist approved by the FDA in 2015 for premenopausal women with HSDD. The key trials (BEGONIA, DAISY, VIOLET) enrolled over 5,900 premenopausal women and showed statistically significant but modest improvements in satisfying sexual events and desire scores. Mean improvement over placebo was approximately 0.5 additional satisfying sexual events per month, which the FDA judged clinically meaningful in the context of patient-reported distress reduction.

Flibanserin is not recommended during breastfeeding. The prescribing information notes that animal studies show drug transfer into breast milk, and no human lactation data exists. The drug also carries a black-box warning for severe hypotension with alcohol use.

Bremelanotide (Vyleesi)

Bremelanotide, a melanocortin receptor agonist given as a subcutaneous injection before anticipated sexual activity, was approved in 2019. The RECONNECT trials enrolled 1,267 premenopausal women and showed improvements in desire and reductions in distress over placebo. Nausea occurred in 40% of participants, and transient blood pressure elevation is a known effect.

Like flibanserin, bremelanotide has no human lactation data. The prescribing information advises against use in breastfeeding women. This means both approved pharmacological options for HSDD are effectively off-limits if you are nursing, which makes postpartum-specific clinical research even more pressing.

Low-Dose Vaginal Estrogen

For women whose low desire is substantially driven by dyspareunia from vaginal atrophy, low-dose vaginal estrogen is a reasonable and well-studied option. The North American Menopause Society Position Statement on vaginal atrophy supports its use in postmenopausal women; the data is extrapolated to lactating women with the caveat that systemic absorption at low doses is minimal. Products include 0.01% estradiol cream, 10 mcg estradiol vaginal tablets (Vagifem), and the 7.5 mcg/day estradiol ring (Estring).

Ospemifene

Ospemifene, a selective estrogen receptor modulator taken orally, is approved for dyspareunia due to menopause-related vaginal atrophy. It has no safety data in lactating women and is not recommended postpartum.

Who Should Consider a Clinical Trial

Clinical trials for postpartum low libido are not only for women who have tried everything. They are also appropriate at earlier stages, particularly when approved options are unavailable due to breastfeeding, when symptoms have persisted beyond six months without clear improvement, or when you want access to structured evaluation and follow-up that routine care may not provide.

Life Stage Considerations

Actively breastfeeding (0-18 months postpartum): Your options are most limited by lactation safety data. Clinical trials studying non-systemic, behavioral, or novel agents with lactation pharmacokinetic monitoring are particularly relevant.

Postpartum but formula-feeding or weaned: You have access to the full range of premenopausal HSDD options and may qualify for trials that exclude lactating participants.

Postpartum with co-existing PCOS: Testosterone dynamics are different in PCOS. Some women with PCOS have higher baseline androgens, which can paradoxically still associate with HSDD depending on SHBG levels. Trials that measure hormonal phenotype at enrollment are more likely to generate useful data for this subgroup.

Postpartum with co-existing depression or anxiety: Antidepressants, particularly SSRIs, independently cause sexual dysfunction in 30-40% of users. A 2020 systematic review in JAMA found that women are more likely than men to experience SSRI-related sexual dysfunction. Trials that account for psychiatric comorbidity and medication use at baseline are essential for this group.

Who Is Typically Excluded

Most trials will exclude women who are currently pregnant, women with active psychiatric hospitalization, women with uncontrolled thyroid disease (because hypothyroidism independently reduces libido), and women using hormonal contraception that could confound desire measurements.

How to Find a Postpartum Libido Clinical Trial

Finding the right trial requires matching your specific clinical picture to inclusion criteria. Here is a concrete approach.

Step 1: Search ClinicalTrials.gov with Targeted Terms

Go to ClinicalTrials.gov and search using these specific term combinations:

• "hypoactive sexual desire disorder" AND "postpartum"
• "female sexual dysfunction" AND "lactation"
• "libido" AND "postpartum" AND "randomized"
• "sexual desire" AND "breastfeeding"

Filter by Status: "Recruiting" and by Sex: "Female." Look at Phase 2 and Phase 3 trials first for the strongest evidence pipeline, but Phase 1 studies matter too if you are a lactating woman because these often collect the pharmacokinetic data that will eventually support approvals.

Step 2: Check Academic OB-GYN and Sexual Medicine Programs

Major academic centers with active sexual medicine programs and postpartum research include the University of British Columbia (Brotto Laboratory), Indiana University (The Kinsey Institute), and Boston University School of Medicine. Their department websites and faculty pages often list active studies before they appear fully in ClinicalTrials.gov.

Step 3: Use the ACOG Patient Education Portal

ACOG's patient-facing resources include referral pathways for sexual health after delivery and can connect you to OB-GYN providers affiliated with research programs.

Step 4: Ask Your Postpartum Provider Directly

Many women do not know they can ask their OB-GYN or midwife about research participation. A specific ask, such as "Are there any studies at this clinic or affiliated institutions looking at libido or sexual function after delivery?" is far more productive than a general question about research.

Questions to Ask Before Enrolling

Before committing to any trial, get clear answers on:

• Does the study allow breastfeeding participants, and if so, how is infant exposure monitored?
• What is the washout period, and will I need to stop breastfeeding temporarily?
• Does the study involve a placebo arm, and for how long?
• Will I receive any active treatment at the end of a placebo-controlled period?
• How many visits are required, and can any be done via telehealth?
• Is there compensation for travel or time?

Hormonal Testing: What Your Clinician Should Measure

If you are seeking care for postpartum low libido, whether in a trial or standard practice, specific labs paint a clearer picture than a general wellness panel.

Useful baseline measurements include:

• Estradiol (E2): To document the degree of suppression, especially in lactating women.
• Total and free testosterone: Bearing in mind that no standardized reference range for postpartum women exists. The Endocrine Society acknowledges that assay variation and lack of normative postpartum data complicate interpretation.
• SHBG (sex hormone-binding globulin): High SHBG (common in estrogen-replete states and with oral contraceptive use) reduces free testosterone independent of total testosterone.
• Prolactin: To confirm lactational suppression and to rule out pathological hyperprolactinemia (pituitary adenoma) when prolactin is elevated in a non-breastfeeding woman.
• TSH: Postpartum thyroiditis affects approximately 5-10% of postpartum women and presents with fatigue and low libido that can be mistaken for HSDD.
• CBC and ferritin: Iron-deficiency anemia is common postpartum and causes fatigue that overlaps with desire loss.

Pregnancy, Lactation, and Contraception: The Safety Summary

This section is mandatory for any discussion touching pharmacological options.

Pregnancy: Most pharmacological treatments for HSDD are contraindicated in pregnancy. Flibanserin is FDA Pregnancy Category not assigned (post-2015 labeling), but animal data showed embryotoxicity at doses overlapping the human therapeutic dose. Bremelanotide is contraindicated in pregnancy; it caused fetal loss in animal studies at doses near the human equivalent. If you are postpartum and have resumed sexual activity, confirm your contraceptive method before any pharmacological HSDD treatment.

Breastfeeding: As detailed above, neither flibanserin nor bremelanotide has human lactation safety data. Low-dose vaginal estrogen has minimal systemic absorption and is generally considered acceptable by most guidelines, with shared decision-making. No systemic hormonal therapy for libido should be started in a breastfeeding woman without explicit discussion of the evidence gap.

Contraception requirements: If you are enrolled in a clinical trial and of reproductive age, most trials will require a highly effective contraceptive method (IUD, implant, or consistent barrier use) throughout the study period. Hormonal contraceptives (combined pill, patch, ring) may be excluded from some trials because they independently affect SHBG and desire measurements.

Postpartum ovulation: Return of ovulation can precede the first postpartum period. ACOG advises that women who do not wish to become pregnant should have a contraceptive plan in place before hospital discharge. This is clinically relevant to trial participation because an unplanned pregnancy would typically require withdrawal from a study.

Red Flags That Warrant Prompt Evaluation Before Any Trial

Before attributing low libido purely to postpartum hormonal changes, your clinician should rule out:

• Undiagnosed postpartum thyroiditis (TSH outside range)
• Postpartum depression or anxiety (Edinburgh Postnatal Depression Scale score above 10)
• Pituitary adenoma (if prolactin is elevated in a non-breastfeeding woman beyond expected recovery)
• Severe iron-deficiency anemia (ferritin below 15 ng/mL)
• Relationship-based sexual aversion that requires couples therapy rather than pharmacotherapy

These conditions need treatment in their own right, and resolving them may restore libido without any additional intervention.